- Company
- Chinese partner terminates agreement with Medytox
- by Nho, Byung Chul Aug 4, 2022 06:04am
- Medytox is having difficulty making entry into the Chinese market. At a presentation on ‘Follow-up regarding Bloomage·Medytox joint venture Medybloom's progress' that was held on the 1st, Bloomage Biotechnology announced that “the company will discontinue the partnership with Medytox and seek opportunities with other botulinum toxin
- Company
- MSD Korea to introduce cancer drug Welireg to Korea
- by Eo, Yun-Ho Aug 3, 2022 06:00am
- MSD is expected to introduce another oncology pipeline to Korea. According to industry sources, MSD Korea has submitted an application for the approval of its oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, ‘Welireg (belzutifan),’ to the Ministry of Food and Drug Safety. The drug had been designated as an orphan drug in
- Company
- Competitivity of K-Pharma-Bio manufacturing facilities rises
- by Lee, Seok-Jun Aug 3, 2022 06:00am
- The competitiveness of K-Pharma/Biomanufacturing facilities are rising. With more and more companies passing inspections by the US FDA (Food and Drug Administration), the institution considered to have the highest standards, the companies that have passed inspections plan to advance into the global market in earnest. Recieves first cGMP ce
- Company
- Lilly appoints new CEO Christopher J. Stokes
- by jung, sae-im Aug 3, 2022 06:00am
- Lilly Korea announced on the 1st that it has appointed Christopher J. Stokes as its new CEO. The new CEO is a pharmaceutical and healthcare expert who has extensive work experience in the global pharmaceutical industry for more than 15 years. He graduated from George Mason University in 2002 and earned a master's degree in public administr
- Company
- Mundipharma is pushing for its first employee reduction
- by jung, sae-im Aug 3, 2022 06:00am
- The impact of Mundipharma's reduction of narcotic analgesics business is also affecting Korean corporations. A major reorganization is taking place, cutting two-thirds of the department's workforce. According to the pharmaceutical industry on the 3rd, Mundipharma is conducting ERP with the aim of finishing at the end of August. The target is
- Company
- LG Chem Applies to FDA for Phase 3 of Gout New Drug
- by jung, sae-im Aug 3, 2022 06:00am
- LG Chem announced on the 1st that it has applied for a phase 3 clinical trial plan for Tigulixostat, a new gout drug developed by the U.S. Food and Drug Administration (FDA). This is the first time that LG Chem has started phase 3 clinical trials of new drugs in global regions such as the U.S. The company's strategy is to significantly exp
- Company
- SK Bioscience has applied for CMA of SKY Covione
- by Kim, Jin-Gu Aug 2, 2022 06:02am
- SK Bioscience announced on the 29th that it has applied for Conditional Marketing Authorization (CMA) of the COVID-19 vaccine to MHRA, a British pharmaceutical regulator. The product name in the UK and Europe is SKY Covione. SK Bioscience explained that it has been conducting a Rolling Review since March to receive prompt approval from MHRA.
- Company
- Dong-A ST, applies for permission to Sugadapa
- by Kim, Jin-Gu Aug 2, 2022 06:01am
- Dong-A ST announced on the 29th that it has applied to the MFDS for the item license of type 2 diabetes complex Sugadapa. Sugadapa is a complex that combines Evogliptin 5mg, the main ingredient of the DPP-4 inhibitor-based diabetes drug Suganon, developed by Dong-A ST, and Dapagliflozin 10mg, the SGLT-2 inhibitor-based drug. DPP-4 inhibitors
- Company
- SK Bioscience applies for CMA of its COVID-19 vaccine to EMA
- by Chon, Seung-Hyun Aug 2, 2022 06:01am
- On the 1st, SK Bioscience announced that it has submitted an application for a Conditional Marketing Authorization (CMA) of its COVID-19 vaccine, ‘SKYCovion,' to the European Medicines Agency (EMA), SKYCovion is a COVID-19 vaccine that induces neutralizing antibody responses by administering an antibody protein made with SK Bioscience’
- Company
- Daewoong Pharmaceutical's biggest quarterly performance ever
- by Kim, Jin-Gu Aug 1, 2022 09:16pm
- Daewoong Pharmaceutical achieved its highest quarterly performance ever. Separately, sales in the second quarter increased 7.6% year-on-year to 293.8 billion won and operating profit increased 25.8% to 33.6 billion won. Both sales and operating profit are all-time highs based on quarterly performance. Earlier, Daewoong Pharmaceutical also set
